Application of pseudoginseng root total saponins and preparations thereof in adjuvant treatment of 'systemic inflammatory response syndrome'

A technology of Panax notoginseng saponins and adjuvant therapy, applied in the field of prevention or adjuvant therapy of "systemic inflammatory response syndrome," can solve the problems of lack of varieties and large economic burden on patients.

Inactive Publication Date: 2011-06-22
KPC PHARM INC
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are relatively few varieties used in the adjuvant treatment of systemic inflammatory response syndrome in China, and there

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pseudoginseng root total saponins and preparations thereof in adjuvant treatment of 'systemic inflammatory response syndrome'
  • Application of pseudoginseng root total saponins and preparations thereof in adjuvant treatment of 'systemic inflammatory response syndrome'
  • Application of pseudoginseng root total saponins and preparations thereof in adjuvant treatment of 'systemic inflammatory response syndrome'

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050]Example 1 The effect of Xuebijing injection and Xuesaitong powder injection on antagonizing endotoxin in vitro

[0051] Objective: To observe whether the drug has the pharmacodynamic effect of antagonizing endotoxin in vitro by dynamic turbidity method, and to compare the effect with Xuebijing at the same time.

[0052] Dilute Xuebijing (10g / L) and Xuesaitong freeze-dried powder with bacterial endotoxin test water (BET water) to a series of required concentrations: 0.15, 0.3, 0.6 and 1.2g / L; The toxin was dissolved in BET water, vortexed for 15 min and then diluted to a concentration of 5×10 5 EU / L (5×10 per liter 5 endotoxin unit), add 10 μl of diluted endotoxin to 1ml of liquid sample and make the final concentration 5×10 3 Add EU / L toxin and incubate at 37°C for 1 hour or 4 hours. In addition, a positive control group (endotoxin plus BET water) and three negative control groups (no pyrogen water, namely BET water, Xuesaitong freeze-dried powder for injection with a...

Embodiment 2

[0059] Example 2 Experimental Study of Xuesaitong Powder Injection Antagonizing Endotoxin in Vivo

[0060] 2.1 Xuesaitong antagonizes the effect of endotoxin (LPS) in rabbits, and compares it with Xuebijing.

[0061] Animals were divided into 6 groups. Five rats in the endotoxin group were given LPS 0.5 mg / kg intravenously. Xuesaitong intervention groups I-III, 5 rats in each group, were given LPS and endotoxin group, and Xuesaitong 20mg / kg, 50mg / kg and 100mg / kg were given after 0.5h. 5 rats in Xuebijing group were given LPS and endotoxin group, and Xuebijing 50mg / kg was given 0.5h later. In the normal control group of 5 rats, LPS 0.5mg / Kg was replaced by normal saline. Each group in the experiment was given blood at 1h, 2h and 4h after administration of LPS or normal saline, and the dynamic turbidity method was used to detect the plasma endotoxin content, and the endotoxin recovery rate was calculated: recovery rate (%)=(endotoxin group value-treatment group value) / endoto...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of pseudoginseng root total saponins and preparations thereof in adjuvant treatment of 'systemic inflammatory response syndrome' (SIRS). The SIRS is effectively removed aiming at an initiation factor of the SIRS, namely endotoxin; the SIRS is inhibited aiming at main damage factors, namely inflammatory mediators, in the development process of the SIRS; and the damage of lung, liver, kidney, small intestines and other important organs caused by the endotoxin is effectively prevented and treated. The damage of vascular endothelial cells caused by the endotoxin is resisted, and the vascular endothelial cells are protected. Severe circulatory disturbance in an SIRS pathological state is improved, and the microcirculation blood flow is increased; therefore, the adjuvant treatment effect on the SIRS is exerted.

Description

[0001] The present invention is a divisional application of the parent case whose application number is 200510127637.8. The filing date of the parent case is December 7, 2005. The title of the invention is "Total Panax notoginseng Saponins and Its Preparations for "Systemic Inflammatory Response Syndrome" use of adjuvant therapy". Technical field: [0002] The present invention relates to the use of Panax notoginseng saponins and preparations containing it, in particular to the use in the prevention or auxiliary treatment of "systemic inflammatory response syndrome (SIRS)". Background technique: [0003] Systemic Inflammatory Response Syndrome (SIRS) is a new concept proposed after in-depth research on the pathophysiological process of infection-inflammation-critical illness in the past 10 years. Excessive release of various inflammatory mediators and excessive activation of inflammatory cells result in a pathophysiological state of systemic excessive inflammatory response. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/258A61P1/00A61P1/16A61P9/00A61P11/00A61P13/12
Inventor 普俊学马维鹏吴琼粉
Owner KPC PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap